The Turkish Journal of Pediatrics 2009 , Vol 51 , Num 1
Successful treatment with gemtuzumab ozogamicin monotherapy in a pediatric patient with resistant relapse of acute myeloid leukemia
Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey Ünal Ş, Çakır M, Kuşkonmaz B, Çetin M, Tuncer AM. Successful treatment with gemtuzumab ozogamicin monotherapy in a pediatric patient with resistant relapse of acute myeloid leukemia. Turk J Pediatr 2009; 51: 69-71.

There are few therapeutic options in relapsed or refractory acute myeloid leukemia patients. CD33 antigen is expressed on approximately 90% of myeloblasts, and gemtuzumab ozogamicin, as a monoclonal antibody directed against the CD33 surface antigen, may be a good target for these patients. Herein, we present a 15-year-old acute myeloid leukemia patient who was resistant at relapse and could achieve remission with gemtuzumab ozogamicin at a total dose of 9 mg/m2, divided into three doses and delivered to hematopoietic stem-cell transplantation; however, the patient relapsed in a short time without application of transplantation. Keywords : pediatric hematology/oncology, acute myeloid leukemia, gemtuzumab ozogamicin, resistant, relapse

Copyright © 2016 turkishjournalpediatrics.org